Newsroom | 36976 results

RAHWAY, N.J., & FOSTER CITY, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash a...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune disorders, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 7,050 shares of the Company’s common stock at an exercise price per share of $21.41, which was th...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for ADSTILADRIN® (nadofaragene firadenovec-vncg), enabling an accelerated water-bath thawing method, completed in about 25 minutes, to enhance efficient clinical preparation for healthcare teams. ADSTILADRIN is the first and only FDA-approved non-replicating intravesical gene-therapy for the treatment of adult patients with high-risk Bacillus Ca...

PECHINO--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), un’azienda biotecnologica globale che dà impulso alla ricerca e sviluppo di farmaci innovativi basati su anticorpi impiegando tecnologie all’avanguardia, oggi ha annunciato una collaborazione strategica con Moonlight Bio, Inc., società biotecnologica con sede a Seattle, pioniera nelle terapie cellulari all’avanguardia. Questa collaborazione mira a sviluppare terapie cellulari all’ava...

LIESTAL, Svizzera--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, “Curatis”) annuncia ricavi aziendali pari a 10,8 milioni di franchi (+57%) per il 2025. Curatis AG ha riportato un aumento organico del fatturato nella sua attività di distribuzione pari al 13%, da 9,5 milioni di franchi a 10,8 milioni di franchi. Il risultato netto è migliorato da una perdita di 4,3 milioni di franchi nel 2024 a una perdita di 1,4 milioni di franchi nel 2025. Ulteriori importanti dichiarazioni Nel settembre 2025...

LIESTAL, Zwitserland--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, “Curatis”) rapporteert een bedrijfsomzet van CHF 10,8m (+57%) voor 2025. Curatis AG kende een organische stijging van de verkoop in haar distributieactiviteiten met 13%, van CHF 9,5m naar CHF 10,8m. Het nettoresultaat verbeterde van een verlies van CHF 4,3m in 2024 naar een verlies van CHF 1,4m in 2025. Andere belangrijke verklaringen In september 2025 werd ons ontwikkelingsplan voor corticorelin gevalideerd tijdens een vergad...

LIESTAL, Suiza--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, «Curatis») obtiene unos ingresos de 10,8 millones de francos suizos (+57 %) para 2025. Curatis AG incrementó las ventas de su negocio de distribución de forma orgánica en un 13 %, de los 9,5 millones de CHF a 10,8 millones de CHF. El resultado neto mejoró, pasando de una pérdida de 4,3 millones de CHF en 2024 a una pérdida de 1,4 millones de CHF en 2025. Otras afirmaciones clave En septiembre de 2025, la FDA validó nuestro plan de d...

LIESTAL, Suisse--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, « Curatis ») annonce un chiffre d’affaires de 10,8 millions CHF (+57 %) pour 2025. Curatis AG a augmenté le chiffre d’affaires de son activité de distribution de manière organique de 13 %, passant de 9,5 millions CHF à 10,8 millions CHF. Le résultat net s’est amélioré, passant d’une perte de 4,3 millions CHF en 2024 à une perte de 1,4 million CHF en 2025. Autres faits marquants En septembre 2025, notre plan de développement pour la...

LIESTAL, Schweiz--(BUSINESS WIRE)--Die Curatis Holding AG (SIX:CURN, „Curatis“) meldet für 2025 einen Umsatz von 10,8 Mio. CHF (+57 %), und die Curatis AG steigerte den Umsatz ihres Vertriebsgeschäfts organisch um 13 % von 9,5 Mio. CHF auf 10,8 Mio. CHF. Das Nettoergebnis verbesserte sich von einem Verlust von 4,3 Mio. CHF im Jahr 2024 auf einen Verlust von 1,4 Mio. CHF im Jahr 2025. Weitere Highlights Bei einem Treffen mit der FDA im September 2025 wurde unser Entwicklungsplan für Corticorelin...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, hosted the second annual Band As One Nashville Concert for the Cure: Trisha Yearwood & Friends, raising $850,000 for breast cancer research, patient care services, and overall awareness of the disease. At The Opry House on Sunday, March 22, 2026, country music icon Trisha Yearwood once again brought together an all-star lineup for an unforgettable evening as meaningful as it was memorable. Bu...